KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Total Liabilities and Equity

Last Annual Value

121.74M

3-Year CAGR

215%

5-Year CAGR

-20%

10-Year CAGR

-11%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Liabilities and Equity

KLRS · NASDAQ
CompanyTotal Liabilities and Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
121.74M
231.8%-15.7%N/A 
150.93M
1.6%-4.9%11.0%
130.94M
7.6%-5.1%N/A
91.03M
-17.1%-21.1%N/A
68.49M
62.2%5.9%N/A
221.10M
-15.4%9.3%N/A
179.84M
4.9%-16.4%-2.6%
59.05M
-37.6%-31.1%N/A
121.40M
16.8%3.4%N/A
53.02M
-20.1%-16.0%N/A
230.86M
1.5%12.5%18.3%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7